+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Biosimilar"

From
From
Infliximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Infliximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Filgrastim - Biosimilar Insight, 2022 - Product Thumbnail Image

Filgrastim - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Rituximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Rituximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
Adalimumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Adalimumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Trastuzumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Trastuzumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
Insulin Glargine- - Biosimilar Insight, 2022 - Product Thumbnail Image

Insulin Glargine- - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Ranibizumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Ranibizumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 150 Pages
  • Global
From
Interferon - Biosimilar Insight, 2022 - Product Thumbnail Image

Interferon - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Somatotropin - Biosimilar Insight, 2022 - Product Thumbnail Image

Somatotropin - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
Loading Indicator

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers. Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more